It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 2 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).
AXON (@Aerospace & Defense) experienced а +3.56% price change this week, while PDSB (@Biotechnology) price change was -10.51% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.45%. For the same industry, the average monthly price growth was +50.50%, and the average quarterly price growth was +33.13%.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.58%. For the same industry, the average monthly price growth was +26.31%, and the average quarterly price growth was +25.79%.
AXON is expected to report earnings on Feb 27, 2024.
PDSB is expected to report earnings on Mar 28, 2024.
Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.@Biotechnology (+5.58% weekly)
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
|AXON||PDSB||AXON / PDSB|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PDSB's Valuation (62) in the Pharmaceuticals Major industry is in the same range as AXON (88) in the Biotechnology industry. This means that PDSB’s stock grew similarly to AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew significantly faster than PDSB’s over the last 12 months.
AXON's SMR Rating (69) in the Biotechnology industry is in the same range as PDSB (99) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to PDSB’s over the last 12 months.
AXON's Price Growth Rating (16) in the Biotechnology industry is somewhat better than the same rating for PDSB (61) in the Pharmaceuticals Major industry. This means that AXON’s stock grew somewhat faster than PDSB’s over the last 12 months.
AXON's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew somewhat faster than PDSB’s over the last 12 months.
1 day ago66%
1 day ago90%
1 day ago78%
1 day ago85%
1 day ago80%
1 day ago89%
1 day ago80%
1 day ago90%
1 day ago79%
1 day ago88%
1 day ago76%
1 day ago86%
1 day ago77%
19 days ago85%
6 days ago71%
6 days ago89%
1 day ago72%
1 day ago81%
1 day ago79%
1 day ago84%
A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.